-
Article
Open AccessComparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
While indirect comparison of infliximab (IFX) and vedolizumab (VDZ) in adults with Crohn’s disease (CD) or ulcerative colitis (UC) shows that IFX has better effectiveness during induction, and comparable effic...
-
Article
Open AccessCorrection: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
-
Article
Open AccessEfficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
No study has performed a face-to-face comparison of biologics after the failure of the first anti-TNF agent in patients with Crohn’s disease (CD). The aim of the study was to compare the efficacy of biologics ...
-
Article
Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study
Patients with inflammatory bowel disease have an increased risk of venous thromboembolism (VTE) and cardiovascular disease (CVD). The study aims to determine the prevalence of CVD and VTE risk factors in a lar...
-
Article
Open AccessComparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis
There are limited comparative data for infliximab and vedolizumab in inflammatory bowel disease patients.
-
Article
Open AccessAdalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
ABP501 is a biosimilar to Reference Adalimumab (HUMIRA®) produced by AMGEN. Adalimumab (ADA) has a marketing authorization for Crohn's disease, ulcerative colitis and other inflammatory or autoimmune diseases....
-
Article
Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn’s Disease
In Crohn’s disease (CD) few data are available on the usefulness of monitoring fecal calprotectin (FC) in the early postoperative setting. We assessed prospectively the accuracy of FC measured 3 months after s...
-
Article
Early venous thromboembolism is a strong prognostic factor in patients with advanced pancreatic ductal adenocarcinoma
There are still controversial data regarding the prognostic value of Venous ThromboEmbolism (VTE) in advanced Pancreatic Ductal AdenoCarcinoma (PDAC) and thromboprophylaxis is poorly prescribed despite interna...
-
Article
No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification
The pharmacokinetic equivalence of dose intensification with adalimumab (ADA) 80 mg every other week (EOW) compared to weekly 40 mg has only been supported by modeling systems.
-
Article
Open AccessNOD2 deficiency increases retrograde transport of secretory IgA complexes in Crohn’s disease
Intestinal microfold cells are the primary pathway for translocation of secretory IgA (SIgA)-pathogen complexes to gut-associated lymphoid tissue. Uptake of SIgA/commensals complexes is important for priming a...
-
Article
Infliximab levels and antibodies in IBD-related peripheral arthralgia
Extra-intestinal manifestations (EIM) are common in inflammatory bowel diseases (IBD) and may affect up to 40% of the patients during the course of the disease. Peripheral arthralgia (PA) is by far the most co...
-
Article
Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD
The primary objective is to assess whether the POC assays to measure infliximab residual trough level in the serum of IBD patients were non-inferior to the ELISA techniques available on the market, and to dete...
-
Article
Outcomes of Bariatric Surgery in Patients with Inflammatory Bowel Disease
-
Article
Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects
Inflammatory bowel disease (IBD) is caused by a dysregulation of the immune system, inducing the production of proinflammatory cytokines and adhesion molecules. A better understanding of the mucosal immune res...
-
Article
Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review
Therapeutic drug monitoring (TDM) of anti-TNF is increasingly used to manage inflammatory bowel diseases (IBD) and rheumatoid arthritis (RA). The cost-effectiveness of this strategy is debated.
-
Article
Open AccessMajor influence of CD4 count at the initiation of cART on viral and immunological reservoir constitution in HIV-1 infected patients
A persistent immune activation is observed in gut during HIV-1 infection, which is not completely reversed by a combined antiretroviral therapy (cART). The impact of the time of cART initiation may highly infl...
-
Article
Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases
Local or national policy, patients’ preferences, safety and/or economic concerns, or reimbursement issues may dictate stop** drug in inflammatory bowel diseases (IBD) patients. Sustained deep remission is an...
-
Article
Open AccessImpact of the level of pre-ART CD4+ T cells in blood on the rectal HIV reservoir in long-term treated men (VIRECT study)
-
Article
La Préparation Par Fleet Phospho Soda (PS) Est-Elle à Risque Chez Des Patients Sans Atteinte Majeure De La Fonction Rénale?
-
Article
Du Journal Faxé d’Hépato-gastro-entérologie
